HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Baclofen in trigeminal neuralgia: its effect on the spinal trigeminal nucleus: a pilot study.

Abstract
Experiments with cats showed that baclofen resembles carbamazepine and phenytoin sodium in its ability to depress excitatory synaptic transmission in the spinal trigeminal nucleus. Baclofen was, therefore, given to 14 patients with refractory trigeminal neuralgia. Ten patients were relieved of the paroxysms of tic douloureux while taking 60 to 80 mg/day of baclofen. A reduction in the dosage of baclofen in six of these patients resulted in a recurrence of painful paroxysms in five patients. Seven patients have been pain-free or almost pain-free on a regimen of baclofen for four to 12 months. Our results suggest that baclofen may be a useful drug in the treatment of trigeminal neuralgia and that our experimental model may successfully predict the efficacy of a drug in the treatment of this condition.
AuthorsG H Fromm, C F Terrence, A S Chattha, J D Glass
JournalArchives of neurology (Arch Neurol) Vol. 37 Issue 12 Pg. 768-71 (Dec 1980) ISSN: 0003-9942 [Print] United States
PMID6255910 (Publication Type: Journal Article)
Chemical References
  • Baclofen
Topics
  • Adult
  • Aged
  • Animals
  • Baclofen (pharmacology, therapeutic use)
  • Cats
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Synaptic Transmission (drug effects)
  • Trigeminal Neuralgia (drug therapy)
  • Trigeminal Nuclei (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: